JAK2V617F status of HPCs assayed from PMF CD34+ cells treated with JAK inhibitor 1, AZ1480, hydroxyurea, or Peg-IFN-α2a
| . | PB granulocytes . | Source of hematopoietic colonies assayed . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary PMF CD34+ cells . | PMF CD34+ cells treated with cytokines alone . | PMF CD34+ treated with cytokines + JAK inhibitor 1 . | PMF CD34+ cells treated with cytokines + AZ1480 . | PMF CD34+ cells treated with cytokines + hydroxurea . | PMF CD34+ cells treated with cytokines + Peg IFN-α 2a . | ||||||||
| JAK2V617F allele burden (%) . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK 2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | |
| Patient 15 | 70* | 77 (30/39)† | 67 (26/39) | 83 (38/46) | 39 (18/46) | 66 (33/50) | 48 (24/50) | 76 (32/42) | 42 (18/43) | 88 (36/41) | 83 (32/41) | 72 (34/47) | 68 (32/47) |
| Patient 16 | 74 | 86 (37/43) | 72 (31/43) | 47 (14/30) | 30 (9/30) | 85 (35/41) | 59 (24/41) | 77 (56/73) | 49 (36/73) | 95 (18/19) | 53 (10/19) | 90 (27/30) | 43 (13/30) |
| Patient 17 | 70 | 93 (13/14) | 86 (12/14) | 100 (14/14 | 100 (14/14) | 93 (14/15) | 93 (14/15) | 94 (17/18) | 83 (15/18) | 82 (9/11) | 64 (7/11) | 100 (11/11) | 100 (11/11) |
| Mean (SD) | 85 (4.63) | 75 (5.69) | 77 (15.62) | 56 (21.99) | 81 (8.01) | 67 (13.54) | 82 (5.84) | 58 (12.66) | 88 (3.76) | 67 (8.76) | 87 (8.19) | 70 (16.50) | |
| . | PB granulocytes . | Source of hematopoietic colonies assayed . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary PMF CD34+ cells . | PMF CD34+ cells treated with cytokines alone . | PMF CD34+ treated with cytokines + JAK inhibitor 1 . | PMF CD34+ cells treated with cytokines + AZ1480 . | PMF CD34+ cells treated with cytokines + hydroxurea . | PMF CD34+ cells treated with cytokines + Peg IFN-α 2a . | ||||||||
| JAK2V617F allele burden (%) . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK 2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | |
| Patient 15 | 70* | 77 (30/39)† | 67 (26/39) | 83 (38/46) | 39 (18/46) | 66 (33/50) | 48 (24/50) | 76 (32/42) | 42 (18/43) | 88 (36/41) | 83 (32/41) | 72 (34/47) | 68 (32/47) |
| Patient 16 | 74 | 86 (37/43) | 72 (31/43) | 47 (14/30) | 30 (9/30) | 85 (35/41) | 59 (24/41) | 77 (56/73) | 49 (36/73) | 95 (18/19) | 53 (10/19) | 90 (27/30) | 43 (13/30) |
| Patient 17 | 70 | 93 (13/14) | 86 (12/14) | 100 (14/14 | 100 (14/14) | 93 (14/15) | 93 (14/15) | 94 (17/18) | 83 (15/18) | 82 (9/11) | 64 (7/11) | 100 (11/11) | 100 (11/11) |
| Mean (SD) | 85 (4.63) | 75 (5.69) | 77 (15.62) | 56 (21.99) | 81 (8.01) | 67 (13.54) | 82 (5.84) | 58 (12.66) | 88 (3.76) | 67 (8.76) | 87 (8.19) | 70 (16.50) | |
The treatment of PMF CD34+ cells with each of JAK inhibitor 1, AZ1480, hydroxyurea, or Peg-IFN-α2a did not substantially reduce the percentage of JAK2V617F+ or JAK2V617F homozygous colonies compared with PMF CD34+ cells exposed to cytokines alone or primary PMF CD34+ cells.
Indicates the percentage of JAK2V617F allele obtained from granulocytes by real-time quantitative kinetic PCR assay using allelic discrimination method.
Each value represents the percentage of colonies (CFU-GM + BFU-E + CFU-Mixed) exhibiting the JAK2V617F mutation or homozygous JAK2V617F allele. The numbers in parentheses denote the actual number of JAK2V617F-positive or homozygous colonies/the total numbers of colonies (CFU-GM + BFU-E + CFU-Mixed) analyzed.